Tag: Orchestra BioMed

Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed’s Virtue® Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership

TOKYO, June 13, 2019 /PRNewswire/ — Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced that it has secured exclusive global development and commercialization rights to Virtue® Sirolimus-Eluting Balloon (SEB) for percutaneous coronary interventions by entering into a strategic partnership with Orchestra BioMed, Inc., a biomedical innovation company providing high-impact solutions […]

Orchestra BioMed™ Receives FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon (SEB)

NEW HOPE, Pa., April 24, 2019 (GLOBE NEWSWIRE) —  Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet healthcare needs, announced today that it has secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Virtue® Sirolimus-Eluting […]

Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer

NEW HOPE, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and […]

Orchestra BioMed™ to Present at the Piper Jaffray Healthcare Conference

NEW HOPE, Pa., Nov. 20, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced that David Hochman, Chairman and Chief Executive Officer, will present a corporate overview at the Piper Jaffray Healthcare […]

Orchestra BioMed™ Announces Completion of $41 Million Financing

NEW HOPE, Pa., Nov. 15, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced the successful final closing of a $41 million private equity financing, which also included the conversion of outstanding […]

Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)

NEW HOPE, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that Professor Petr Neuzil, M.D., Head of the Department of Cardiology of Na Homolce Hospital in Prague, Czech […]

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions

NEW HOPE, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has appointed three key members to its management team. Joining the […]

Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board

NEW HOPE, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the appointment of three new members to its Strategic Advisory Board (“SAB”). Joining the Company’s SAB is Gary J. Pruden, former […]

Orchestra BioMed™ Bolsters Leadership Team with Appointment of Inessa Wheeler as Vice President, Strategy and Marketing

NEW HOPE, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has appointed Inessa Wheeler, MBA, as Vice President of Strategy […]

Orchestra BioMed™ Announces Presentation of Positive 2-Year Clinical Results and Program Update for BackBeat® Cardiac Neuromodulation Therapy at TCT 2018

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, presented positive 2-year clinical results from its multicenter clinical trial for BackBeat® Cardiac Neuromodulation Therapy (CNT) at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San […]